Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Paediatric care

Teething products containing lidocaine made P medicine

From 2019, lidocaine-containing products will only be available for sale following the advice of a pharmacist, following safety recommendations from the Medicines and Healthcare products Regulatory Agency.

Baby aisle at supermarket


Lidocaine-containing teething products will no longer be available in supermarkets from 2019

Teething products which contain lidocaine will be sold as a pharmacy-only (P) medicine from 2019, the UK’s drugs safety watchdog, the Medicines and Healthcare products Regulatory Agency (MHRA), has announced.

The decision means that the products will not be available over-the-counter in the current wide range of settings including supermarkets, following a review which found a lack of evidence that they relieved the symptoms of teething.

Patient advice about the products is also being updated following the results of the MHRA review.

The Agency said lidocaine-containing teething products should only be used as a “second-line treatment” when non-medicinal options, such as a cooled teething ring, failed to provide the necessary relief for babies and children.

The MHRA, which recommended parents and carers discuss teething relief options with their community pharmacist, concluded that the risks of using lidocaine-containing products for soothing symptoms of teething was “very small” given wide use of the products.

The review was prompted by the US Food and Drug Administration’s (FDA’s) decision that oral viscous lidocaine 2% solution available on prescription should not be used for treating teething problems in babies and young people because it posed serious health risks, including death. The FDA added that a boxed warning label should be displayed on the product.

In a statement, the MHRA said: “Our review, which began following the FDA changes, looked at the safety of these products and measures have been recommended to ensure their safer use. Pharmacists and healthcare professionals are best placed to provide guidance on supporting parents through teething if non-medicinal methods are not sufficient.”

The MHRA confirmed that oral viscous lidocaine 2% solution is not available in the UK for infants.

The Royal Pharmaceutical Society has worked with the MHRA on a Quick Reference Guide on the use of oral lidocaine-containing products. The guide, aimed at pharmacy teams, covers the changes that have been made since the review and explains how to advise parents seeking advice or treatment for teething infants.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2018.20205907

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.